Axillary Reverse Mapping (ARM) Technique (ARM)
Invasive Breast Cancer, Ductal Carcinoma in Situ of the Breast
About this trial
This is an interventional treatment trial for Invasive Breast Cancer focused on measuring axillary reverse mapping (ARM), sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), lymphedema, breast cancer, surgery
Eligibility Criteria
Inclusion Criteria: women diagnosed with invasive breast cancer or ductal carcinoma in situ receiving the following treatment:
- mastectomy and sentinel lymph node biopsy
- breast conserving surgery or mastectomy and axillary lymph node dissection
- completion axillary lymph node dissection after positive sentinel lymph node biopsy
- cases receiving neo-adjuvant therapy (chemotherapy or hormonal therapy) who are having axillary lymph node dissection as part of their surgical treatment -
Exclusion Criteria:
- males with breast cancer
- women less than 18 years of age
- known allergic reaction to patent blue dye
- pregnant
- previous radiation therapy to affected side
- clinical N2/N3 disease -
Sites / Locations
- St. Joseph's Healthcare
- Juravinski Hospital and Cancer Centre
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
axillary reverse mapping
standard axillary surgery
Axillary reverse mapping and sentinel lymph node biopsy (ARM/SLNB) or Axillary reverse mapping and axillary lymph node dissection (ARM/ALND)
The control group will have standard sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND) without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).